Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank A Holtkamp

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Diabetes Care|April 29, 2011
Monitoring kidney function and albuminuria in patients with diabetesHiddo J Lambers Heerspink, Frank A Holtkamp, Dick de Zeeuw, et al.
The International Journal of Risk & Safety in Medicine|June 7, 2014
Quality of drug label information on QT interval prolongationMiriam J Warnier, Frank A Holtkamp, Frans H Rutten, et al.
Drug Discovery Today|June 29, 2014
Safety information on QT-interval prolongation: comparison of European Union and United States drug labelingMiriam J Warnier, Frank A Holtkamp, Frans H Rutten, et al.
Kidney International|March 23, 2012
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockersHiddo J Lambers Heerspink, Frank A Holtkamp, Hans-Henrik Parving, et al.
European Heart Journal|March 23, 2011
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trialsFrank A Holtkamp, Dick de Zeeuw, Pieter A de Graeff, et al.
Kidney International|April 1, 2011
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionFrank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, et al.
European Heart Journal|April 22, 2017
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpointsPatrick Rossignol, Rajiv Agarwal, Bernard Canaud, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Diabetes Care|April 29, 2011
Monitoring kidney function and albuminuria in patients with diabetesHiddo J Lambers Heerspink, Frank A Holtkamp, Dick de Zeeuw, et al.
The International Journal of Risk & Safety in Medicine|June 7, 2014
Quality of drug label information on QT interval prolongationMiriam J Warnier, Frank A Holtkamp, Frans H Rutten, et al.
Drug Discovery Today|June 29, 2014
Safety information on QT-interval prolongation: comparison of European Union and United States drug labelingMiriam J Warnier, Frank A Holtkamp, Frans H Rutten, et al.
Kidney International|March 23, 2012
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockersHiddo J Lambers Heerspink, Frank A Holtkamp, Hans-Henrik Parving, et al.
European Heart Journal|March 23, 2011
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trialsFrank A Holtkamp, Dick de Zeeuw, Pieter A de Graeff, et al.
Kidney International|April 1, 2011
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionFrank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, et al.
European Heart Journal|April 22, 2017
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpointsPatrick Rossignol, Rajiv Agarwal, Bernard Canaud, et al.
Pageof 1